Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial ...

Kidney transplant recipients with active or high risk for antibody-mediated rejection reported transplant benefits but still experienced physical restrictions and psychological concerns, according to ...

MediBeacon’s CEO, Steven Hanley, will present at the upcoming Stifel Healthcare Conference in New York on Tuesday, Nov. 11, 2025 at 5:40 AM PST / 8:40 AM EST. Media and Investor Contact Carrie ...

Unicycive Therapeutics (UNCY) announced that it will present new oxylanthanum carbonate, OLC, data at the American Society of Nephrology, ASN, ...

The poster will be made available on the Presentations & Research page of Unicycive’s website following the poster ...

Reverting to pre-COVID telehealth policies could reduce access to care for kidney transplant recipients who live in ...

ASN’s Kidney Week 2025 is happening November 5-9, 2025 at the George R. Brown Convention Center in Houston, Texas.

Nephrology & Hypertension, Deepak Jasuja, M.D., a nephrologist, collaborates with a team of cardiologists to treat patients ...

The global Renal Cyst Treatment Market is poised for significant expansion, growing from an estimated USD 203.2 million in ...

Insights from ASN 2025, including anticipated presentations, key takeaways, and how new research in CKD affects patient care.